KRAS and cholangiocarcinoma: In the RFS cohort, TNM stage, chemotherapy adjuvant, Kirsten rat sarcoma viral oncogene (KRAS) mutation and Cartes d'Identité des Tumeurs (CIT) molecular subtype were related to CC RFS (P < 0.05); in the OS cohort, age, TNM stage, KRAS mutation and CIT molecular subtype were related to CC OS (P < 0.05).